Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Mar 23, 2022 6:32pm
97 Views
Post# 34539615

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stay focused on the facts

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stay focused on the factsI agree --this seems fairly typical for most ADC trials I've read about as they just leave the chemo near the environment and not into the targeted tumor. For whatever reason, eye issues seem to be prevalent with ADCs, along with the usual lists.  I believe that's why Trodelvy had a long setback in the 1b/2a timeframe and had to rework a number of issues. 

qwerty22 wrote:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201164/

Here's a paper that compares Trop2 expression in normal cells versus cancer cells. It's the target for Trodelvy that Gilead paid $21 billion for and did nearly $400 million in sales last year on it's so far very limited label. If you read that paper, which I assume somebody at Gilead did, you might wonder how it ever got approved. That paper says the Trop2 protein is expressed in some normal tissue at least as highly as in tumour cells. This is potentially an obvious source of off-target toxicity. This drug comes with a black box warning but is still used by clinicians.


Another ADC Padcev had close to 50% of it's patients experience peripheral neuropathy and 50% had ocular problems. Both were mostly low grade and manageable but there are instructions to discontinue this drug for grade 3 or higher.

These are the circumstances and profiles of approved drugs. This is the ballpark th1902 will hopefully be playing in. Spatrap can make the calls he chooses to make. I just don't think I have enough info to do that yet. For me we are still mostly in the dark.



<< Previous
Bullboard Posts
Next >>